Prognostic value of baseline SUVmax in FL
| Study . | Type of study . | No patients . | HT . | PFS . |
|---|---|---|---|---|
| Strati et al53 | Retrospective | 346 | 18 pts (5%) with HT: 12 HT in SUVmax < 18 and 6 (11%) in SUVmax > 18 (P = .04) | Inferior OS in SUVmax >18 |
| GALLIUM54 | Clinical trial | 549 | 15 pts (2.7%) with HT: no difference in SUVmax | No association of bSUVmax with PFS |
| PET in PRIMA55 | Retrospective | 58 | No pts with HT | No association of bSUVmax with PFS |
| FOLLCOLL56 | Retrospective | 181 | 2 pts with HT | Inferior PFS in SUVmax < 9.4, no difference in OS |
| RELEVANCE58 | Clinical trial | 406 | No evaluated | No association of bSUVmax with PFS |
| Trotman et al59 | Clinical trials | 439 | Not reported | Inferior OS in PET+ |
| Study . | Type of study . | No patients . | HT . | PFS . |
|---|---|---|---|---|
| Strati et al53 | Retrospective | 346 | 18 pts (5%) with HT: 12 HT in SUVmax < 18 and 6 (11%) in SUVmax > 18 (P = .04) | Inferior OS in SUVmax >18 |
| GALLIUM54 | Clinical trial | 549 | 15 pts (2.7%) with HT: no difference in SUVmax | No association of bSUVmax with PFS |
| PET in PRIMA55 | Retrospective | 58 | No pts with HT | No association of bSUVmax with PFS |
| FOLLCOLL56 | Retrospective | 181 | 2 pts with HT | Inferior PFS in SUVmax < 9.4, no difference in OS |
| RELEVANCE58 | Clinical trial | 406 | No evaluated | No association of bSUVmax with PFS |
| Trotman et al59 | Clinical trials | 439 | Not reported | Inferior OS in PET+ |